Amicus Therapeutics (FOLD) Scheduled to Post Earnings on Monday

Amicus Therapeutics (NASDAQ:FOLDGet Rating) is scheduled to post its quarterly earnings results before the market opens on Monday, May 9th. Analysts expect Amicus Therapeutics to post earnings of ($0.24) per share for the quarter. Amicus Therapeutics has set its FY 2022 guidance at EPS.Individual interested in listening to the company’s earnings conference call can do so using this link.

Amicus Therapeutics (NASDAQ:FOLDGet Rating) last posted its quarterly earnings results on Thursday, February 24th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.15). Amicus Therapeutics had a negative return on equity of 87.21% and a negative net margin of 81.98%. The firm had revenue of $82.15 million for the quarter, compared to analysts’ expectations of $82.57 million. During the same period last year, the business earned ($0.27) earnings per share. On average, analysts expect Amicus Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

FOLD opened at $7.08 on Monday. Amicus Therapeutics has a fifty-two week low of $6.98 and a fifty-two week high of $12.63. The business has a 50-day moving average of $8.71 and a 200-day moving average of $9.95. The company has a quick ratio of 3.90, a current ratio of 4.09 and a debt-to-equity ratio of 1.27.

FOLD has been the topic of a number of recent analyst reports. The Goldman Sachs Group initiated coverage on Amicus Therapeutics in a research note on Wednesday, April 13th. They issued a “neutral” rating on the stock. Cantor Fitzgerald cut their price objective on Amicus Therapeutics from $16.00 to $15.00 and set an “overweight” rating on the stock in a research note on Thursday, January 13th. StockNews.com initiated coverage on Amicus Therapeutics in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Finally, SVB Leerink cut their price objective on Amicus Therapeutics from $16.00 to $14.00 and set an “outperform” rating on the stock in a research note on Thursday, February 24th. Five research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, Amicus Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $15.14.

In other news, COO Bradley L. Campbell sold 10,940 shares of Amicus Therapeutics stock in a transaction that occurred on Friday, March 18th. The stock was sold at an average price of $10.00, for a total transaction of $109,400.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Ellen Rosenberg sold 11,018 shares of Amicus Therapeutics stock in a transaction that occurred on Thursday, April 7th. The stock was sold at an average price of $9.06, for a total value of $99,823.08. Following the sale, the insider now directly owns 302,952 shares in the company, valued at approximately $2,744,745.12. The disclosure for this sale can be found here. Insiders sold a total of 24,172 shares of company stock worth $227,024 in the last ninety days. Insiders own 2.10% of the company’s stock.

Several large investors have recently made changes to their positions in FOLD. William Blair Investment Management LLC grew its holdings in shares of Amicus Therapeutics by 25.4% during the 4th quarter. William Blair Investment Management LLC now owns 2,476,721 shares of the biopharmaceutical company’s stock worth $28,606,000 after purchasing an additional 501,749 shares in the last quarter. BlackRock Inc. boosted its stake in Amicus Therapeutics by 1.1% in the 4th quarter. BlackRock Inc. now owns 19,810,348 shares of the biopharmaceutical company’s stock valued at $228,810,000 after buying an additional 224,150 shares in the last quarter. UBS Group AG boosted its stake in Amicus Therapeutics by 129.0% in the 3rd quarter. UBS Group AG now owns 327,846 shares of the biopharmaceutical company’s stock valued at $3,131,000 after buying an additional 184,656 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in Amicus Therapeutics in the 4th quarter valued at $558,000. Finally, Millennium Management LLC acquired a new stake in Amicus Therapeutics in the 2nd quarter valued at $451,000.

About Amicus Therapeutics (Get Rating)

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.

See Also

Earnings History for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.